The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and impressive returns is clear, the linked risks are also significant.